清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Early rhythm-control therapy for atrial fibrillation in patients with a history of stroke: a subgroup analysis of the EAST-AFNET 4 trial

医学 心房颤动 冲程(发动机) 随机对照试验 人口 不利影响 内科学 子群分析 物理疗法 急诊医学 儿科 置信区间 机械工程 环境卫生 工程类
作者
Märit Jensen,Anna Suling,Andreas Metzner,Renate B. Schnabel,Katrin Borof,Andreas Goette,Karl Georg Hæusler,Antonia Zapf,Karl Wegscheider,Larissa Fabritz,Hans‐Christoph Diener,Götz Thomalla,Paulus Kirchhof
出处
期刊:Lancet Neurology [Elsevier]
卷期号:22 (1): 45-54 被引量:14
标识
DOI:10.1016/s1474-4422(22)00436-7
摘要

Patients with atrial fibrillation and a history of stroke are at high risk of recurrent stroke and cardiovascular complications. In the EAST-AFNET 4 trial we showed that a systematic strategy of early rhythm control was associated with a lower risk of cardiovascular outcomes than usual care in patients with atrial fibrillation diagnosed in the past 12 months. In this pre-specified subgroup analysis we aimed to assess whether a strategy of early rhythm control is safe and can prevent adverse cardiovascular outcomes compared with usual care in such patients.EAST-AFNET 4 was a randomised, open-label trial with blinded-outcome assessment done at 135 hospitals and secondary care practices in 11 European countries. Adults with early atrial fibrillation (ie, diagnosed ≤12 months before enrolment) were randomly assigned (1:1) to either early rhythm control or usual care, with stratification according to site and variable block lengths used for concealment. The first primary outcome was time to first occurrence of the composite of cardiovascular death, ischaemic or haemorrhagic stroke, or hospital admission with worsening of heart failure or acute coronary syndrome. The second primary outcome was the number of nights spent in hospital in 1 year. The primary safety outcome was the composite of any death, stroke, or serious adverse events related to rhythm-control therapy. Here we present the results of these outcomes in patients with a history of stroke. Analyses were done in the intention-to-treat population. EAST-AFNET 4 is registered with ClinicalTrials.gov (NCT01288352), EudraCT (2010-021258-20), and ISRCTN (ISRCTN04708680).Between July 28, 2011, and Dec 30, 2016, 2789 patients were randomly assigned in the EAST-AFNET 4 trial to either early rhythm control (n=1395) or usual care (n=1394). Of these patients, five had no information on history of stroke and were excluded from this subgroup analysis. 217 (8%) patients had a history of stroke, of whom 110 were assigned to early rhythm control and 107 to usual care. The median age of participants with a history of stroke was 72·0 years (IQR 66·0-76·0). 95 (44%) participants were female and 122 (56%) were male. During a median follow-up of 4·7 years (3·5-6·4) for patients with a history of stroke, a first primary outcome event occurred in 18 (16%) of 110 patients in the early rhythm-control group (3·7 per 100 person-years) and 33 (31%) of 107 in the usual care group (7·4 per 100 person-years; hazard ratio [HR] 0·52, 95% CI 0·29-0·93). The mean number of nights spent in hospital per year was 5·1 (SD 13·2) for patients with a history of stroke assigned to early rhythm control and 6·6 (10·1) for those assigned to usual care (incidence rate ratio 0·87, 95% CI 0·55-1·38). Among patients with a history of stroke, primary safety events occurred in 17 (15%) patients in the early rhythm-control group versus 30 (28%) in the usual care group.In this prespecified subgroup analysis in patients with recently diagnosed atrial fibrillation and a history of stroke, the effects of early rhythm control were consistent with the findings of the primary analysis. As the evidence from this subgroup analysis is considered supportive and exploratory, further research is needed to confirm the safety and efficacy of this approach in patients with a history of stroke.German Ministry of Education and Research, German Center for Cardiovascular Research (DZHK), Atrial Fibrillation Network (AFNET), European Heart Rhythm Association, St Jude Medical-Abbott, Sanofi, and the German Heart Foundation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
退伍的三毛完成签到 ,获得积分10
10秒前
PVK完成签到 ,获得积分10
14秒前
dream2000完成签到 ,获得积分10
22秒前
成佳木完成签到 ,获得积分10
48秒前
2012csc完成签到 ,获得积分0
1分钟前
QC发布了新的文献求助200
1分钟前
南风完成签到 ,获得积分10
1分钟前
加菲丰丰完成签到,获得积分0
1分钟前
宇文宛菡完成签到 ,获得积分10
1分钟前
LienAo完成签到 ,获得积分10
1分钟前
a46539749完成签到 ,获得积分10
1分钟前
zhilianghui0807完成签到 ,获得积分10
2分钟前
benben完成签到,获得积分0
2分钟前
几米完成签到 ,获得积分10
2分钟前
房天川完成签到 ,获得积分10
2分钟前
荣安安完成签到 ,获得积分10
2分钟前
天才小能喵完成签到 ,获得积分10
3分钟前
儒雅的夏翠完成签到,获得积分10
3分钟前
冷静新烟完成签到,获得积分10
3分钟前
CodeCraft应助陈陈陈采纳,获得10
3分钟前
3分钟前
3分钟前
陈陈陈发布了新的文献求助10
4分钟前
lilylch完成签到 ,获得积分10
4分钟前
4分钟前
风趣香之完成签到,获得积分10
5分钟前
poki完成签到 ,获得积分10
5分钟前
放牧星空发布了新的文献求助10
5分钟前
scinature完成签到,获得积分10
5分钟前
木南大宝完成签到 ,获得积分10
6分钟前
chichenglin完成签到 ,获得积分10
6分钟前
田雨完成签到 ,获得积分10
6分钟前
认真的蘑菇完成签到 ,获得积分10
6分钟前
留下记忆完成签到 ,获得积分10
6分钟前
scarlet完成签到 ,获得积分10
7分钟前
姚老表发布了新的文献求助10
7分钟前
zyjsunye完成签到 ,获得积分10
7分钟前
emchavezangel发布了新的文献求助10
7分钟前
elisa828完成签到,获得积分10
7分钟前
emchavezangel完成签到,获得积分10
7分钟前
高分求助中
Thermodynamic data for steelmaking 3000
Teaching Social and Emotional Learning in Physical Education 900
Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition With Psychotic Screen (SCID-I/P W/ PSY SCREEN) 400
Cardiology: Board and Certification Review 400
[Lambert-Eaton syndrome without calcium channel autoantibodies] 300
Transformerboard III 300
Aspirin inhabits proliferation and promotes apoptosis of pancreatic cancer cells via PI3K/Akt/mTOR signaling pathway 200
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2358253
求助须知:如何正确求助?哪些是违规求助? 2065323
关于积分的说明 5156237
捐赠科研通 1794339
什么是DOI,文献DOI怎么找? 896333
版权声明 557563
科研通“疑难数据库(出版商)”最低求助积分说明 478398